2020 Southwest Prostate Cancer Symposium 

Virtual CME Symposium

December 12, 2020 – 8:00am-5:30pm (EST)

innovations in urologic practice logo

A Must Attend Event!

The 2020 Virtual Southwest Prostate Cancer Symposium (SPCS 2020) is intended for urologists, radiation oncologists, medical oncologists, and other healthcare professionals involved in the treatment of prostate cancer. It will educate the attendees about advances in the management of localized and advanced prostate cancer, with a focus on imaging, technology, and training in the related devices.

The goal of this educational program is to equip urologists, radiation oncologists, medical oncologists, and other healthcare professionals involved in prostate cancer care with the up-to-date clinical knowledge and tools they need to best treat their patients. The program aims to provide a technical update on all aspects of diagnosis and treatment of localized and advanced disease.

Program Co-Chair

Nelson N. Stone, MD

Professor of Urology and Radiation Oncology
Icahn School of Medicine at Mount Sinai
New York, New York

Program Co-Chair

Richard G. Stock, MD

Professor of Radiation Oncology
Director of Genito-Urinary Radiation Oncology
Icahn School of Medicine at Mount Sinai
New York, New York

Attend Lectures and Panel Discussions

Watch Experts Discuss and Demonstrate Urologic Procedures

Connect with peers and experts

How the Virtual CME Symposia Works

The virtual, Zoom-based event is open to all Grand Rounds in Urology members and the larger urology community.

Agenda

The virtual 2020 Southwest Prostate Cancer Symposium offers a robust online program with two multi-track sessions, including CME lectures, panels virtual hands-on training demonstrations,networking and more. Join us for the full virtual conference broadcast on Saturday, December 12, 2020, from 8:00am-5:30pm (EST).

Saturday, December 12, 2020

(ALL TIMES IN EASTERN TIME ZONE)

8:00am-8:10am

Welcome and Introduction
Program Co-Chairs: Nelson N. Stone, MD, and Richard G. Stock, MD

8:10am-10:30am

SESSION 1 – Identifying Candidates for Focal Therapy

8:10am-8:30am

Pathologist’s Perspective
M. Scott Lucia, MD   

8:30am-8:50am

Transrectal mpMRI Fusion Biopsy
Leonard S. Marks, MD

8:50am-9:10am

Freehand Transperineal Prostate Biopsy Under Local Anesthesia
Michael A. Gorin, MD

9:10am-9:30am

Can One Biopsy Event Identify Focal Therapy Candidates?
Nelson N. Stone, MD

9:30am-9:50am

Application of MRI Fusion Biopsy Results to Focal Therapy
Leonard S. Marks, MD

9:50am-10:30am

Panel Discussion
Moderator: Nelson N. Stone, MD

10:30am-11:00am

Exhibits and Networking

11:00am-12:15pm

SESSION 2 – Limiting Radiation Injury

11:00am-11:20am

Does Anatomic Rectal Displacement Improve Dosimetry and Reduce Injury?
Jon S. Prescott, MD

11:20am-11:40am

Radiation Dose Requirements for Local Disease Eradication
Nelson N. Stone, MD

11:40am-12:00pm

Brachytherapy and Focal Therapy Outcomes
Richard G. Stock, MD

12:00pm-12:15pm

Panel Discussion
Moderator: Richard G. Stock, MD

12:15pm-1:45pm

Spotlight Product Theaters

12:15pm-12:45pm

Spotlight Product Theater 1
Important Evidence-Based Changes in the Metastatic
Castration-Sensitive Prostate Cancer Treatment Landscape
Speaker: Edward M. Uchio, MD, FACS, CPI
Sponsored by Astellas Pharma US and Pfizer Oncology

12:45pm-1:15pm

Spotlight Product Theater 2
Erleada: TITAN and New Data for SPARTAN Final Analysis
Speaker: Matthew B. Rettig, MD
Supported by Janssen Biotech

1:15pm-1:45pm

Spotlight Product Theater 3
An Innovative Abiraterone Acetate, YONSA®
Speaker: Raoul S. Concepcion, MD
Sponsored by Sun Pharma

1:45pm-5:30pm

SESSION 3 – Virtual Hands-on Training

1:45pm-2:30pm

Office-Based and Transperineal mpMRI Fusion Biopsy
Michael A. Gorin, MD

2:30pm-3:15pm

Transrectal mpMRI Fusion Biopsy
Leonard Marks, MD

3:15pm-4:00pm

Transperineal Hydrogel Placement
Jon S. Prescott, MD

4:00pm-4:45pm

Brachytherapy Focal Therapy Technique
Richard G. Stock and Nelson N. Stone

4:45pm-5:30pm

Panel Discussion and Closing Remarks
Nelson N. Stone, MD

Invited Faculty

Co-Chair

Nelson N. Stone, MD

Professor of Urology and Radiation Oncology
Icahn School of Medicine at Mount Sinai
New York, New York

Co-Chair

Richard G. Stock, MD

Professor of Radiation Oncology
Director of Genito-Urinary Radiation Oncology
Icahn School of Medicine at Mount Sinai
New York, New York

Michael A. Gorin, MD

Urologist
Urology Associates & UPMC Western Maryland
Cumberland, Maryland

M. Scott Lucia, MD

Vice Chair of the Department of Pathology
Director of Anatomic Pathology​
Director of the Prostate Diagnostic Laboratory
University of Colorado, Denver
Aurora, Colorado

Leonard S. Marks, MD

Professor and DeKernion Endowed Chair in Urology
Professor-in-Residence
UCLA Medical Center
Los Angeles, California

Jon S. Prescott, MD

Medical Director
Northern Ohio Regional Cancer Center
Brook Park, Ohio

CME Information

ACCREDITATION/CREDIT DESIGNATION
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical College of Wisconsin (MCW) and Carden Jennings Publishing Co., Ltd. (CJP). The Medical College of Wisconsin (MCW)  is accredited by ACCME to provide continuing medical education for physicians.

MCW designates this live activity for a maximum of 4.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

TARGET AUDIENCES
This activity is designed for radiation oncologists, urologists, medical oncologists, primary care specialists, and other healthcare professionals involved in the diagnosis and management of prostate cancer.

EDUCATIONAL OBJECTIVES
At the conclusion of the activity, participants should be able to:

  • Assess which diagnostic tests help distinguish a lower versus higher-risk patient
  • Recognize how the decrease in early detection has resulted in prostate cancers presenting at a more advanced stage
  • Describe technical advances, including robotic radical prostatectomy, image-guided external beam radiotherapy (IGRT), proton beam therapy, hypofractionated radiotherapy (SBRT), computer-guided brachytherapy, and mpMRI, and demonstrate their role in prostate cancer treatment and detection
  • Identify appropriate patients for radiation-based treatments such as brachytherapy, brachytherapy boost, IMRT/IGRT, proton therapy robotic and open prostatectomy, and focal therapy taking serum and genetic influences into account
  • Assess the implications of local failure after radiation therapy and introduce new radio-protective technologies
  • Discuss treatment of advanced disease, specifically in the non-metastatic CRPC disease state
  • Contribute to group discussions regarding potential future research directions to address how we can improve inter-observer agreement and overall quality, develop machine-learning techniques, and improve current technology for staging high-risk disease and for disease monitoring after therapy.

EDUCATIONAL METHODS
Lectures | Debates | Question and Answer Sessions | Panel Discussions | Live Surgical Case Demonstrations

EVALUATION
Evaluation by questionnaire will address program content, presentation, and possible bias.

Support Opportunities

To inquire about support opportunities, please contact:

Marc Weathersby, Chief Marketing Officer
Tel:434-817-2000, x193    Cell: 434-989-5508
Fax 434-817-2020    mweathersby@cjp.com

Exhibit and Sponsor Prospectus

Registration

During these times, Grand Rounds in Urology and the Southwest Prostate Cancer Symposium are committed to you and helping your practice run as best as it can.

Sponsors

PLATINUM SPONSORS

Astellas Pharma US and Pfizer Oncology   •    Janssen Biotech

SILVER SPONSORS

Sun Pharma

SUPPORTERS

Accuray   •   Bayer   •   Blue Earth Diagnostics
Boston Scientific   •   Foundation Medicine   •   Hitachi Healthcare
IsoAid   •   IsoRay   •   Koelis   •   Perineologic
Progenics Pharmaceutical/Lantheus Holdings

EXHIBITORS

Accuray   •    American Brachytherapy Society
Astellas Pharma US and Pfizer Oncology
Bayer   •    Blue Earth Diagnostics  •    Boston Scientific
Foundation Medicine   •    Hitachi Healthcare
IsoAid   •    IsoRay   •    Janssen Biotech   •    Koelis
Perineologic   •    Progenics Pharmaceutical/Lantheus Holdings  •    Sun Pharma

=

Have Questions? Contact Us.